Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2005-09-14
2008-09-30
Campell, Bruce (Department: 1648)
Chemistry: molecular biology and microbiology
Vector, per se
C435S069100
Reexamination Certificate
active
07429481
ABSTRACT:
The present invention relates to viruses that are engineered to contain a surface ligand molecule which targets the virus to a cell of interest. In particular non-limiting embodiments, the cell of interest is desirably ablated and may be a cancer cell, an infected cell, a cell exhibiting a non-malignant proliferative disorder, or a cell of the immune system. Alternatively, the cell of interest is a target for gene therapy.
REFERENCES:
patent: 6432699 (2002-08-01), Meruelo et al.
patent: 6596268 (2003-07-01), Coffey et al.
patent: 6649157 (2003-11-01), Coffey et al.
patent: 2002/0192824 (2002-12-01), Meruelo et al.
patent: 2003/0049845 (2003-03-01), Meruelo et al.
Paul et al. AIDS Research and Human Retroviruses, 1993, vol. 9, No. 10. pp. 963-970.
Schubert et a. J. Virol. 1992, vol. 66, No. 33, pp. 1579-1589.
Somia et al., Proc. Natl. Acad. Sci. USA, 1995, vol. 92, pp. 75570-7574.
Davis et al., 2006, Structural polyprotein [contains: Spike glycoprotein E2]. GenBank Accession No. P11259.
Lindencrona, J. A. et al., CD4+ T cell-mediated HER-2
eu-specific tumor rejection in the absence of B cells. International Journal of Cancer 109: 259-264.
Miller, M. A., C. L. Lavine, S. D. Klas, L. M. Pfeffer, and M. A. Whitt, 2004, Recombinant replication-restricted VSV as an expression vector for murine cytokines. Protein Expression & Purification 33: 92-103.
Aichele et al., 2003, Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses. J Immunol. 171(3):1148-55.
Bander, N.H. et al., 2003, Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol. 30: 667-676.
Bergman, I. et al., 2003, Vesicular stomatitis virus. expressing a chimeric Sindbis glycoprotein containing an Fc antibody binding domain targets to Her2
eu overexpressing breast cancer cells. Virology 316: 337-347.
Bucheit, A.D. et al., 2003, An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol. Ther. 7: 62-72.
Cohen, R.B., 2003, Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer. 2: 246-251.
Ercolini, A. M. et al., 2003, Identification and characterization of the immunodominant rat HER-2
eu 1\1HC class I epitope presented by spontaneous mammary tumors from HER-2
eu-transgenic mice. Journal of Immunology 170 :4273-4280.
Martin, F. et al., 2003, Targeted retroviral infection of tumor cells by receptor cooperation. J. Virol. 77: 2753-2756.
Nemunaitis, J. et al., 2003, Pilot trial of intravenous infusion of a replication-selective adenovirus (Onyx-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Therapy 10: 341-352.
Peng, K.W., et al., 2003, Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood 101: 2557-2562.
Stojdl, D. F., et al., 2003, VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
Wannesson, L. and Ghielmini, M., 2003, Overview of Antibody Therapy in BCell Non-Hodgkin's Lymphoma. Clin Lymphoma. 4 Suppl 1: S5-S12.
Aarts, W. M. et al., 2002, Vector-based vaccinelcytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res. 62: 5770-5777.
Ali, S. A., et al., 2002, Tumor regression induced by intratumor therpy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity. Journal of Immunology 168:3512-3519.
Buteau, C. et al., 2002, Challenges in the development of effective peptide vaccines for cancer. [Review] [90 refs]. Mayo Clinic Proceedings 77: 339-349.
Chew, H. K., 2002, Medical management of breast cancer: today and tomorrow. [Review] [75 refs]. Cancer Biotherapy & Radiopharmaceuticals 17: 137-149.
Fernandez, M. et al., 2002, Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. Journal of Virology 76: 895-904.
Hindle, W., 2002, Breast cancer: introduction. [Review] [33 refs]. Clinical Obstetrics & Gynecology 45: 738-745.
Hu, H. M. et al., 2002, CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells. Journal of Immunology 169: 4897-4904.
Mami-Chouaib, F. et al., 2002, Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen. Immunol Rev. 188: 114-121.
Miller, G. et al., 2002, Endogenous granulocyte-macrophage colony-stimulating factor overexpression in vivo results in the long-term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function. Journal of Immunology 169: 2875-2885.
Mwangi, W., et al., 2002, DNA-encoded fetal liver tyrosine kinase 3 ligand and granulocyte macrophage-colony stimulating factor increase dendritic cell recruitment to the inoculation site and enhance antigen-specific CD4+. T cell responses induced by DNA vaccination of outbred animals. Journal of Immunology 169: 3837-3846.
Perez-Diez, A. et al., 2002, Intensity of the vaccine elicited immune response determines tumor clearance. Journal of Immunology 168: 338-347.
Pu, Z., et al., 2002, Distinct recognition by two subsets of T cells of an MHC class peptide complex. Proceedings of the National Academy of Sciences of the United States of America 99: 8844-8849.
Ring, C. J., 2002, Cytolytic viruses as potential anti-cancer agents. [Review] [159 refs]. Journal of General Virology 83: 491-502.
Stern, B. V. et al., 2002, Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity. Journal of Immunology 168: 6099-6105.
Vogel, C. L. et al., 2002, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 20: 719-726.
Yamazaki, M. et al., 2002, Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Therapy 9: 64-74.
Yang, Y. A. et al., 2002, Life˜ime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.[comment]. Journal of Clinical Investigation 109: 1607-1615.
Zhang, W. et al., 2002, Placement of the structural proteins in Sindbis virus. J Virol. 76: 11645-11658.
Balachandran, S., M. Porosnicu, and G. N. Barber, 2001, Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. Journal of Virology 75: 3474-3479.
Baselga, J. and Albanell, J., 2001, Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol. 12 Suppl 1: S35-41.
Beatty, G. and Y. Paterson, 2001, IFN-gamma-dependent inhibition of tumor angiogenesis by tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. Journal of Immunology 166: 2276-2282.
Bergman, I. et al., 2001, Treatment of meningeal breast cancer xenografts in the rat using an anti-p185/HER2 antibody. Clin. Cancer Res. 7: 2050-2056.
Chu E and DeVita, V.T., 2001, Principles of Cancer Management: Chemotherapy, p. 289-306. In H. S. R. S. De Vita VT Jr. (ed.), Cancer: Principles and Practice of Oncology. Lippincott, Williams & Wikins, Philadelphia.
Danova, M., Porta, C., Ferrari, S., and Riccardi, A., 2001, Strategies of medical treatment for metastatic breast cancer (Review). [Review] [64 refs]. International Journal of Oncology 19: 733-739.
de Mattos CA, de Mattos CC, and Rupprecht CE. 2001. Rhabdoviruses, pp. 1245-1277. In Fundamental Virology, (D. Knipe et al (eds.)); Lippincott Williams & Wilkins, Philadelphia.
Elzey, B. D et al., 2001, Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (AL V AC)
Bergman Ira
Whitaker-Dowling Patricia
Baker & Botts L.L.P.
Campell Bruce
Li Bao Qun
University of Pittsburgh
LandOfFree
Targeting viruses using a modified sindbis glycoprotein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Targeting viruses using a modified sindbis glycoprotein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeting viruses using a modified sindbis glycoprotein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3991981